



Join us for a
Exhibitor Spotlight
Presentation

ASN Kidney Week 2023

VELPHORO®
(sucroferric oxyhydroxide)
chewable tablets

Overcoming the challenges of phosphate management with a high-potency approach



Featured Speaker:

Anjay Rastogi, MD, PhD

Professor and Clinical Chief of Nephrology
David Geffen School of Medicine UCLA
UCLA Health Los Angeles, CA

Friday November 3, 2023

12:00 - 12:45PM

Pennsylvania Convention Center

Theater #1, Exhibit Hall B
(enter at Exhibit Hall C)

Supported by: Fresenius Medical Care Renal Pharmaceuticals
The Exhibitor Spotlight is not a Continuing Education (CE) activity

Seating is first come, first served.
Please arrive 15 minutes prior to start time.

 **FRESENIUS
MEDICAL CARE**
RENAL PHARMACEUTICALS

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

- Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed.
- Do not swallow whole.
- Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
- In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
- Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional Safety Information, please see the Full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care Customer Service at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

© 2023 Fresenius Medical Care. All Rights Reserved.

Fresenius Medical Care and the triangle logo are trademarks of Fresenius Medical Care Holdings, Inc. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.

Distributed by: Fresenius Medical Care North America,
Waltham, MA 02451 PN 105636-01 Rev A 09/2023